Bill Haulbrook, Peter Flynn, and Han Le, represented Vivasure Medical, an Ireland-based developer of next-generation percutaneous vessel closure technology, in its $215 million acquisition by global medical technology company, Haemonetics Corporation (HAE). Choate has long served as Vivasure’s IP counsel and supported the company throughout the diligence process for this acquisition. The transaction marks a significant milestone for Vivasure as it integrates into Haemonetics’ portfolio of vascular and interventional products.